About Protom International
At ProTom International, proton therapy is not only what we do, it is all we do. Our proton therapy operations are headquartered in the USA — our manufacturing, development, research, service and proton therapy projects are all managed and operated right here in America.
Officers and Directors:
Stephen L. Spotts – President and Chief Executive Officer; Member, Board of Directors
James P. Bennett – Chairman of the Board
Thomas Blanton – Member, Board of Directors
Halden Conner – Member, Board of Directors
Robert E. Curry, Ph.D. – Member, Board of Directors
Philip A. Incarnati – Member, Board of Directors
Gregory R. Lane – Member, Board of Directors
Thomas Carman – Senior Vice President, Business Development
Nancy E. Corbett – Senior Vice President, Operations
Dmitri Sivan, Ph.D. – Vice President, International and Scientific Relations
Robert Herron – Vice President, Information Technology
Jon Frank – Vice President, Sales and Development
Stephen Sledge – Vice President, Marketing
Vahagn Nazaryan, Ph.D. – Vice President, Physics
Cheryl Smith – Director, Administration and Client Relations
Ed Rule – Director, Quality Control and Regulatory Affairs
Lauri K. Reichert, Director of Finance and Accounting.
Scientific Advisory Board:
Jay Flanz, Ph.D. – Technical Advisor
Hanne Kooy, Ph.D. – Consultant, Clinical Advisor
Consultants:
Hogan Lovells LLP – FDA counsel
Reglera – Regulatory Guidance
|
|
McLaren Proton Therapy Center
A partnership between McLaren Health Care and ProTom International, a Texas-based health care technology company |
|
|
|
|
New Progress For Cancer Treatment
Find out what makes Radiance 330* different from previous generations of technology. |
|
|
|
